Contrasting CareDx (CDNA) and Its Competitors

CareDx (NASDAQ: CDNA) is one of 21 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare CareDx to related businesses based on the strength of its institutional ownership, earnings, profitability, valuation, dividends, analyst recommendations and risk.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a summary of current ratings for CareDx and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CareDx 0 0 4 0 3.00
CareDx Competitors 110 455 531 17 2.41

CareDx currently has a consensus target price of $8.88, suggesting a potential downside of 1.50%. As a group, “Medical laboratories” companies have a potential upside of 15.30%. Given CareDx’s rivals higher possible upside, analysts plainly believe CareDx has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares CareDx and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CareDx $48.32 million -$55.46 million -11.70
CareDx Competitors $1.13 billion $76.65 million 215.33

CareDx’s rivals have higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

51.5% of CareDx shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are owned by institutional investors. 5.4% of CareDx shares are owned by company insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

CareDx has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, CareDx’s rivals have a beta of 1.24, meaning that their average share price is 24% more volatile than the S&P 500.


This table compares CareDx and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CareDx -114.79% -349.65% -22.88%
CareDx Competitors -118.65% -181.74% -42.76%


CareDx rivals beat CareDx on 8 of the 13 factors compared.

CareDx Company Profile

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with's FREE daily email newsletter.

Leave a Reply